


Active Filter(s):
Details:
Proceeds from Series B will be used to expand Octant’s platform capabilities and pipeline, advance its proprietary drug discovery technology, and generate extensive datasets that map the relationships between drug candidates, genetics, and biochemical mechanism of human cells.
Lead Product(s): Chaperon Therapy
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Catalio Capital Management
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing April 21, 2022